Equities analysts expect Infinity Pharmaceuticals Inc. (NASDAQ:INFI) to post earnings per share (EPS) of ($0.25) for the current quarter, according to Zacks. Zero analysts have provided estimates for Infinity Pharmaceuticals’ earnings, with estimates ranging from ($0.27) to ($0.22). Infinity Pharmaceuticals reported earnings per share of ($0.46) in the same quarter last year, which suggests a positive year over year growth rate of 45.7%. The company is scheduled to issue its next earnings report on Tuesday, March 13th.
According to Zacks, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($0.95) to ($0.90). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.07) per share, with EPS estimates ranging from ($1.10) to ($1.04). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.06. The firm had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $14.70 million. During the same period in the previous year, the firm posted ($0.39) EPS.
In related news, President Lawrence E. Bloch bought 500,000 shares of the company’s stock in a transaction dated Wednesday, December 6th. The shares were acquired at an average price of $1.81 per share, for a total transaction of $905,000.00. Following the completion of the transaction, the president now directly owns 580,944 shares in the company, valued at $1,051,508.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.81% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Zacks Investment Management acquired a new stake in shares of Infinity Pharmaceuticals in the second quarter valued at about $101,000. Ameriprise Financial Inc. acquired a new stake in shares of Infinity Pharmaceuticals in the second quarter valued at about $130,000. JPMorgan Chase & Co. acquired a new stake in shares of Infinity Pharmaceuticals in the third quarter valued at about $135,000. Clear Harbor Asset Management LLC acquired a new stake in shares of Infinity Pharmaceuticals in the fourth quarter valued at about $312,000. Finally, FMR LLC acquired a new stake in shares of Infinity Pharmaceuticals in the second quarter valued at about $349,000. Institutional investors and hedge funds own 54.34% of the company’s stock.
Infinity Pharmaceuticals (NASDAQ:INFI) opened at $2.09 on Monday. Infinity Pharmaceuticals has a fifty-two week low of $0.93 and a fifty-two week high of $3.84. The firm has a market cap of $105.94, a price-to-earnings ratio of -1.83 and a beta of 2.82.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.